

## LETTER to the EDITOR

# Salvage Chemotherapy with Weekly Paclitaxel for Metastatic Melanoma

*Asian Pac J Cancer Prev*, 16 (6), 2581

### Dear Editor

Although new therapeutic strategies have come up in the past few years in metastatic malignant melanoma, salvage therapy option which is systemic chemotherapy has not lost its importance. Therefore, we evaluated 23 patients with metastatic malignant melanoma administrated weekly paclitaxel 80 mg/m<sup>2</sup> as salvage therapy from October 2008 to August 2013 in a multicenter Anatolian Society of Medical Oncology (ASMO) study, retrospectively. Tumor responses were evaluated every 2-3 months by the Response Evaluation Criteria in Solid Tumors criteria version 1.1 and toxicities were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0.

Before the induction of paclitaxel, all patients had received the combination of temozolamide and cisplatin or temozolamide alone or dacarbazine alone. Targeted therapies were not given because they were not provided at that time in our country. Eighteen patients had received the paclitaxel in second-line and 5 patients in third-line. Median age was 57 (min-max: 29-79) years. Fifteen patients were male and 8 female. In terms of primer tumor site, 8 patients in head-neck, 6 patients in lower limb, 3 patients in upper limb, 3 patients in trunk and 3 patients in uvea. All patients had multiple nodal and/or visceral metastases at administration of paclitaxel. Complete response were not observed but 2 patients (8.7%) had partial response. Stable disease was observed in 8 patients (34.7%). Response rate (RR) was 8.7% and clinical response rate was 43.4%. Median progression free survival (PFS) was 12 weeks (95% CI: 9.67-14.32) and median overall survival (OS) was 40 weeks (95% CI: 21.22-58.78) (Table 1). Six patients (26%) experienced neuropathy, all grade 1-2. Other dose-limiting toxicities were not observed.

The prognosis for advanced metastatic melanoma is poor. Temozolamide and dacarbazine have been the most commonly used cytotoxic agent. However, the objective response rate is under 20% (Patel et al., 2011). The combination of carboplatin and paclitaxel or paclitaxel alone have shown modest activity in advanced melanoma

**Table 1. Survival Analyses of Salvage Weekly Paclitaxel in Patients with Metastatic Melanoma**

Patients Number	Median PFS (weeks)	Median OS (weeks)	Response Rate (%)	Stable Disease Rate (%)
23	12	40	8.7	34.7

(Zimpfer-Rechner et al., 2003). Paclitaxel has been evaluated in phase II trials in melanoma (Zimpfer-Rechner et al., 2003; Walker et al., 2005). In a study of salvage therapy for metastatic melanoma among 27 patients, no patient responded with CR or PR and median PFS was found 1.8 months and median OS 7.6 months (Walker et al., 2005). As second-line therapy, a randomized study of weekly paclitaxel versus carboplatin plus paclitaxel was stopped because the overall response rate was below 10% in both arms and there was no difference in time to progression and median survival between the two arms (Zimpfer-Rechner et al., 2003). Paclitaxel with or without carboplatin had only limited efficacy as second-line therapy for metastatic melanoma. Even if new molecular-targeted therapy including vemurafenib, ipilimumab, MEK inhibitors, anti PD-1 and anti PD-L1 become effective and actual therapy modalities, they always should be set above the existing chemotherapy for salvage therapy of metastatic melanoma (Grimaldi et al., 2014; Mamalis et al., 2014).

### References

- Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA (2014). Novel approaches in melanoma prevention and therapy. *Cancer Treat Res*, **159**, 443-55.
- Mamalis A, Garcha M, Jagdeo J (2014). Targeting the PD-1 pathway: a promising future for the treatment of melanoma. *Arch Dermatol Res*, **306**, 511-9.
- Patel PM, Suci S, Mortier L, et al (2011). EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). *Eur J Cancer*, **47**, 1476-83.
- Walker L, Schalch H, King DM, et al (2005). Phase II trial of weekly paclitaxel in patients with advanced melanoma. *Melanoma Res*, **15**, 453-9.
- Zimpfer-Rechner C, Hofmann U, Figl R et al (2003). Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the dermatologic cooperative oncology group (DeCOG). *Melanoma Res*, **13**, 531-6.

### Ersin Ozaslan<sup>1\*</sup>, Asude Aksoy<sup>2</sup>, Ozge Gumusay<sup>3</sup>, Erkan Arpacı<sup>4</sup>, Veli Berk<sup>1</sup>

Department of Medical Oncology, <sup>1</sup>Erciyes University Faculty of Medicine, Kayseri, <sup>2</sup>Inonu University Faculty of Medicine, Malatya, <sup>3</sup>Gazi University Faculty of Medicine, Ankara, <sup>4</sup>Sakarya University Faculty of Medicine, Sakarya, Turkey \*For correspondence: [dr-ozaslan@hotmail.com](mailto:dr-ozaslan@hotmail.com)